Related Research Articles
Ebola, also known as Ebola virus disease (EVD) and Ebola hemorrhagic fever (EHF), is a viral hemorrhagic fever in humans and other primates, caused by ebolaviruses. Symptoms typically start anywhere between two days and three weeks after infection. The first symptoms are usually fever, sore throat, muscle pain, and headaches. These are usually followed by vomiting, diarrhoea, rash and decreased liver and kidney function, at which point some people begin to bleed both internally and externally. It kills between 25% and 90% of those infected – about 50% on average. Death is often due to shock from fluid loss, and typically occurs between six and 16 days after the first symptoms appear. Early treatment of symptoms increases the survival rate considerably compared to late start. An Ebola vaccine was approved by the US FDA in December 2019.
Zaire ebolavirus, more commonly known as Ebola virus, is one of six known species within the genus Ebolavirus. Four of the six known ebolaviruses, including EBOV, cause a severe and often fatal hemorrhagic fever in humans and other mammals, known as Ebola virus disease (EVD). Ebola virus has caused the majority of human deaths from EVD, and was the cause of the 2013–2016 epidemic in western Africa, which resulted in at least 28,646 suspected cases and 11,323 confirmed deaths.
Favipiravir, sold under the brand name Avigan among others, is an antiviral medication used to treat influenza in Japan. It is also being studied to treat a number of other viral infections, including SARS-CoV-2. Like the experimental antiviral drugs T-1105 and T-1106, it is a pyrazinecarboxamide derivative.
The 2013–2016 epidemic of Ebola virus disease, centered in Western Africa, was the most widespread outbreak of the disease in history. It caused major loss of life and socioeconomic disruption in the region, mainly in Guinea, Liberia and Sierra Leone. The first cases were recorded in Guinea in December 2013; later, the disease spread to neighbouring Liberia and Sierra Leone, with minor outbreaks occurring in Nigeria and Mali. Secondary infections of medical workers occurred in the United States and Spain. In addition, isolated cases were recorded in Senegal, the United Kingdom and Italy. The number of cases peaked in October 2014 and then began to decline gradually, following the commitment of substantial international resources.
ZMapp is an experimental biopharmaceutical drug comprising three chimeric monoclonal antibodies under development as a treatment for Ebola virus disease. Two of the three components were originally developed at the Public Health Agency of Canada's National Microbiology Laboratory (NML), and the third at the U.S. Army Medical Research Institute of Infectious Diseases; the cocktail was optimized by Gary Kobinger, a research scientist at the NML and underwent further development under license by Mapp Biopharmaceutical. ZMapp was first used on humans during the Western African Ebola virus epidemic, having only been previously tested on animals and not yet subjected to a randomized controlled trial. The National Institutes of Health (NIH) ran a clinical trial starting in January 2015 with subjects from Sierra Leone, Guinea, and Liberia aiming to enroll 200 people, but the epidemic waned and the trial closed early, leaving it too statistically underpowered to give a meaningful result about whether ZMapp worked.
TKM-Ebola was an experimental antiviral drug for Ebola disease that was developed by Arbutus Biopharma in Vancouver, Canada. The drug candidate was formerly known as Ebola-SNALP.
Recombinant vesicular stomatitis virus–Zaire Ebola virus (rVSV-ZEBOV), also known as Ebola Zaire vaccine live and sold under the brand name Ervebo, is an Ebola vaccine for adults that prevents Ebola caused by the Zaire ebolavirus. When used in ring vaccination, rVSV-ZEBOV has shown a high level of protection. Around half the people given the vaccine have mild to moderate adverse effects that include headache, fatigue, and muscle pain.
An Ebola virus epidemic in Sierra Leone occurred in 2014, along with the neighbouring countries of Guinea and Liberia. On 18 March 2014, Guinean health officials announced the outbreak of a mysterious hemorrhagic fever "which strikes like lightning". It was identified as Ebola virus disease and spread to Sierra Leone by May 2014. The disease was thought to have originated when a child from a bat-hunting family contracted the disease in Guinea in December 2013.
An epidemic of Ebola virus disease in Guinea from 2013 to 2016 represents the first ever outbreak of Ebola in a West African country. Previous outbreaks have been confined to several countries in Sub-Saharan Africa.
An epidemic of Ebola virus disease occurred in Liberia from 2014 to 2015, along with the neighbouring countries of Guinea and Sierra Leone. The first cases of virus were reported by late March 2014. The Ebola virus, a biosafety level four pathogen, is an RNA virus discovered in 1976.
Ebola vaccines are vaccines either approved or in development to prevent Ebola. As of 2022, there are only vaccines against the Zaire ebolavirus. The first vaccine to be approved in the United States was rVSV-ZEBOV in December 2019. It had been used extensively in the Kivu Ebola epidemic under a compassionate use protocol. During the early 21st century, several vaccine candidates displayed efficacy to protect nonhuman primates against lethal infection.
Organizations from around the world responded to the West African Ebola virus epidemic. In July 2014, the World Health Organization (WHO) convened an emergency meeting with health ministers from eleven countries and announced collaboration on a strategy to co-ordinate technical support to combat the epidemic. In August, they declared the outbreak an international public health emergency and published a roadmap to guide and coordinate the international response to the outbreak, aiming to stop ongoing Ebola transmission worldwide within 6–9 months. In September, the United Nations Security Council declared the Ebola virus outbreak in the West Africa subregion a "threat to international peace and security" and unanimously adopted a resolution urging UN member states to provide more resources to fight the outbreak; the WHO stated that the cost for combating the epidemic will be a minimum of $1 billion.
This article covers the timeline of the 2014 Ebola virus epidemic in West Africa and its outbreaks elsewhere. Flag icons denote the first announcements of confirmed cases by the respective nation-states, their first deaths, and their first secondary transmissions, as well as relevant sessions and announcements of agencies such as the World Health Organization (WHO), the U.S. Centers for Disease Control (CDC), and NGOs such as Doctors Without Borders; medical evacuations, visa restrictions, border closures, quarantines, court rulings, and possible cases of zoonosis are also included.
Ebola virus disease in Mali occurred in October 2014, leading to concern about the possibility of an outbreak of Ebola in Mali. A child was brought from Guinea and died in the northwestern city of Kayes. Mali contact traced over 100 people who had contact with the child; tracing was completed in mid-November with no further cases discovered. In November, a second unrelated outbreak occurred in Mali's capital city, Bamako. Several people at a clinic are thought to have been infected by a man traveling from Guinea. On January 18, Mali was declared Ebola-free after 42 days with no new cases. There had been a cumulative total of eight cases with six deaths.
The Ebola virus epidemic in West Africa has had a large effect on the culture of most of the West African countries. In most instances, the effect is a rather negative one as it has disrupted many Africans’ traditional norms and practices. For instance, many West African communities rely on traditional healers and witch doctors, who use herbal remedies, massage, chant and witchcraft to cure just about any ailment. Therefore, it is difficult for West Africans to adapt to foreign medical practices. Specifically, West African resistance to Western medicine is prominent in the region, which calls for severe distrust of Western and modern medical personnel and practices.(see Ebola conspiracies below.)
The following lists events that happened during 2014 in Guinea.
Cases of the Ebola virus disease in Nigeria were reported in 2014 as a small part of the epidemic of Ebola virus disease which originated in Guinea that represented the first outbreak of the disease in a West African country. Previous outbreaks had been confined to countries in Central Africa.
There is no cure or specific treatment for the Ebola virus disease that is currently approved for market, although various experimental treatments are being developed. For past and current Ebola epidemics, treatment has been primarily supportive in nature.
In March 2014, the World Health Organization (WHO) reported a major Ebola outbreak in Guinea, a western African nation, the disease then rapidly spread to the neighboring countries of Liberia and Sierra Leone with smaller outbreaks occurring in Senegal, Nigeria, and Mali; the resulting West African Ebola virus epidemic is the largest Ebola outbreak ever documented.
References
- 1 2 "Guinea's Grand Imam Pulls No Punches In His Ebola Message". NPR.org. 26 January 2015. Retrieved 7 February 2015.
 | This Guinean biographical article is a stub. You can help Wikipedia by expanding it. |
 | This biographical article about a person notable in connection with Islam is a stub. You can help Wikipedia by expanding it. |